The results of a randomized, double-blind, placebo-controlled trial investigating the effects of ellagic acid on multiple metabolic markers among people with non-alcoholic fatty liver disease (NAFLD) were recently published in BMC Complementary Medicine and Therapies. This trial enrolled 44 non-obese participants between ages 18 and 55 (mean age ~ 40) diagnosed with NAFLD by hepatic…